Belzutifan FDA Approval Status
FDA Approved: No
Generic name: belzutifan
Company: Merck
Treatment for: Renal Cell Carcinoma
Belzutifan (MK-6482) is a novel, potent and selective inhibitor of HIF-2α in development for the treatment of patients with von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC).
Development Timeline for belzutifan
| Date | Article |
|---|---|
| Mar 16, 2021 | Merck Receives Priority Review From FDA for New Drug Application for HIF-2α Inhibitor Belzutifan (MK-6482) |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.